Catalent Rises on Report Lonza Group Offered to Buy It

Catalent Inc., a company offering technologies that deliver drugs into targeted cells and tissues, surged after Reuters reported that Lonza Group AG offered to buy it.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.